APR 27, 2026 · REGULATORY LABEL UPDATE
FDA supplemental approval: Lenalidomide (REMS)
U.S. Food and Drug Administration
FDA supplemental approval of a risk evaluation and mitigation strategy (REMS) for an existing drug; this is an administrative action, not a clinical evidence record.
Reported
Approval date2026-04-27
Submission typeREMS supplement
Approved strengths5 mg, 15 mg, 20 mg, 25 mg oral capsules